从2027年开始,中低收入国家每年将通过印度非专利药物获得40美元的艾滋病毒预防注射(lenacapavir)。 Starting in 2027, low- and middle-income countries will get a $40 annual HIV prevention injection, lenacapavir, via Indian generics.

从2027年开始,每年两次通过印度通用制造商在120个中低收入国家进行艾滋病毒预防注射(lenacapavir),每年40美元,大大低于美国目前约28 000美元的价格。 Starting in 2027, a twice-yearly HIV prevention injection, lenacapavir, will be available for $40 per year in 120 low- and middle-income countries through Indian generic manufacturers, a dramatic drop from the current U.S. price of about $28,000. 该药物由Gilead研制,由世卫组织推荐,可提供高达100%的功效,并可提高高危群体对药物的遵守率。 The drug, developed by Gilead and recommended by the WHO, offers up to 100% efficacy and could improve adherence among high-risk groups. 该倡议由盖茨基金会和UnitedAid供资,旨在到2027年扩大准入范围,南非预计将在2025年11月前批准该倡议。 Funded by the Gates Foundation and Unitaid, the initiative aims to expand access by 2027, with South Africa expected to approve it by November 2025. 专家们敦促印度迅速推出国内许可证和更广泛的全球许可,以确保公平获取和减少新的艾滋病毒感染。 Experts urge swift domestic rollout in India and broader global licensing to ensure equitable access and reduce new HIV infections.